Scientific Publication

The BENEFIT Trial: Where do we go from here?

author(s) Pecoul, B. - Batista, C. - Stobbaerts, E. - Ribeiro, I. - Vilasanjuan, R. - Gascon, J.
from UK Foreign, Commonwealth & Development Office (FCDO)
permalink open
themes
citation

Pecoul B, Batista C, Stobbaerts E, Ribeiro I, Vilasanjuan R, Gascon J, et al. (2016) The BENEFIT Trial: Where Do We Go from Here? PLoS Neglected Tropical Diseases 10(2) https://doi.org/10.1371/journal.pntd.0004343

Publications and datasets provided via GARDIAN

Abstract

The commentary in this article discusses the results and implications of the recently published BENEFIT trial.The Benznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT) trial was designed to evaluate the safety and efficacy of benznidazole in patients with Chagasic cardiomyopathy. In the next 5 years, we can now project that 200,000 people living with Chagas disease will die from heart disease and related complications. We urgently need to redouble our efforts to identify and treat young people who are still in the early stages of their illness, but ultimately we need to find better treatments and new cures. This is an output from the Drugs for Neglected Diseases initiative (DNDi) programme

Open original